Rivaroxaban News and Research

RSS
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

New guidance can help physicians determine best oral blood thinners for patients

New guidance can help physicians determine best oral blood thinners for patients

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

New supplement covers current knowledge and methods for management of AAICH

New supplement covers current knowledge and methods for management of AAICH

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

AAN guideline suggests people with irregular heartbeat to take oral anticoagulants to prevent stroke

AAN guideline suggests people with irregular heartbeat to take oral anticoagulants to prevent stroke

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

August edition of NPS RADAR includes reviews for new medicines listed on PBS

August edition of NPS RADAR includes reviews for new medicines listed on PBS

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen receives complete response letter from FDA for XARELTO sNDA

Study: New genetic marker predicts warfarin dose in African-Americans

Study: New genetic marker predicts warfarin dose in African-Americans

New AAN guideline provides direction for use of blood thinners during surgery

New AAN guideline provides direction for use of blood thinners during surgery

University of Michigan Stroke Program study examines use of tPA in stroke patients

University of Michigan Stroke Program study examines use of tPA in stroke patients